Abstract
Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have